Press Releases 10.19.2017
Moderna Named One of Global Biopharmaceutical Industry’s Top Employers in Science Magazine’s Annual Survey
Cambridge, Mass. -- Oct. 19, 2017—Moderna Therapeutics, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has been named one of the global biopharmaceutical industry’s top employers in Science’s and Science Careers’ 2017 Top Employers Survey. The annual survey polled employees in the biotechnology, biopharmaceutical, pharmaceutical, and related industries across the globe to determine the 20 best employers in these industries. This is the third consecutive year that Moderna has been named to this prestigious list, which includes some of the most notable companies in the industry. Moderna ranked sixth on the list this year.
“We are very proud to once again be named a top employer in the biopharma industry and be included among this prestigious group of companies,” said Stéphane Bancel, CEO at Moderna. “We have made significant strides this year to advance our mission to deliver on the promise of mRNA science for patients. This progress is all due to the contributions and commitment of our remarkable team and their unparalleled ability to be bold, creative, agile and undaunted. We continue to attract world-class talent to Moderna, and we take very seriously our responsibility to create an environment where our employees can develop and grow in their careers and contribute meaningfully every day. We’ll continue to push the boundaries of innovation while striving to be an exemplary employer and a model corporate citizen.”
Moderna’s medicines use mRNA, a fundamental component of human biology, to direct cells in the body to make and express proteins to prevent and fight disease. The company’s development pipeline currently consists of 16 mRNA medicines across several therapeutic areas including infectious diseases, cancer/immuno-oncology, cardiovascular disease and rare liver diseases. Clinical studies are underway for seven of these development candidates, with the remaining nine advancing toward the clinic. In addition, Moderna is progressing multiple research programs toward development.
Science and Science Careers’ web-based survey includes results from 6,950 responses from readers of Science, as well as other survey invitees. The survey took place in the spring of 2017. Survey participants were located in North America, Europe and Asia/Pacific Rim, with 94 percent working in biotechnology, biopharmaceutical and pharmaceutical companies. Rankings were determined by an independent research firm that analyzed survey responses rating companies based on various characteristics including a research-driven environment, easy adaptation to change and financial strength.
The complete feature can be found at www.sciencecareers.org/TopEmployers2017. The rankings also will appear in the October 20, 2017, print issue of Science.
About Moderna Therapeutics
Moderna is a clinical stage pioneer of messenger RNA (mRNA) therapeutics and vaccines, an entirely new drug technology that directs the body’s cells to produce intracellular or secreted proteins. With its breakthrough platform, Moderna is developing mRNA vaccines and therapeutics as a new class of medicines for a wide range of diseases and conditions, in many cases by addressing currently undruggable targets. Moderna is developing its innovative mRNA medicines for infectious diseases, cancer (immuno-oncology), rare liver diseases, cardiovascular diseases and pulmonary diseases, through proprietary development and collaborations with strategic partners.
Headquartered in Cambridge, Mass., privately held Moderna currently has strategic agreements with AstraZeneca, Merck and Vertex Pharmaceuticals, as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense; the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS); and the Bill & Melinda Gates Foundation. To learn more, visit www.modernatx.com.